Interleukin-13 IgGFc fusion protein
Alternative Names: IL-13 antagonist - Wyeth; IL-13-α-2-IgGFc fusion protein; Interleukin-13 antagonist - Wyeth; sIL-13R-α-2-FcLatest Information Update: 03 Oct 2011
Price :
$50 *
At a glance
- Originator Wyeth
- Class Antiasthmatics
- Mechanism of Action Interleukin 13 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Allergic asthma; Hepatic fibrosis
Most Recent Events
- 17 Feb 2006 No development reported - Preclinical for Allergic asthma in USA (unspecified route)
- 17 Feb 2006 No development reported - Preclinical for Hepatic fibrosis in USA (unspecified route)
- 29 Jan 2003 Genetics Institute is now called Wyeth